Abbott acquires Exact Sciences (NASDAQ: EXAS) in $105-per-share cash deal

Rhea-AI Filing Summary

EXACT SCIENCES CORP director Kimberly J. Popovits reported the disposition of her remaining common shares in connection with the company’s merger with Abbott Laboratories. On March 23, 2026, Exact Sciences became a wholly owned subsidiary of Abbott under a previously signed merger agreement.

At the effective time of the merger, each outstanding share of Exact Sciences common stock was converted into the right to receive $105.00 in cash, without interest. All restricted shares subject to vesting or other restrictions were deemed fully vested, cancelled, and similarly converted into the cash merger consideration, leaving Popovits with no remaining Exact Sciences common stock.

Insights

M&A and equity markets analyst

Filing confirms Exact Sciences’ all-cash sale to Abbott at $105 per share.

This Form 4 shows director Kimberly J. Popovits disposing of her Exact Sciences common stock as part of the closing of the merger with Abbott Laboratories. Each share was converted into the right to receive $105.00 in cash.

The transactions are coded as dispositions to the issuer, reflecting cancellation of shares rather than open-market selling. All restricted shares vested and were cancelled for the same cash consideration, indicating a full equity cash-out at closing. Equity holders’ future exposure shifts from Exact Sciences stock performance to Abbott’s overall corporate profile.

Subsequent disclosures from Abbott and any remaining integration updates will frame how the acquired business contributes within Abbott after the March 23, 2026 closing.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Popovits Kimberly J

Role Director

Type	Security	Shares	Price	Value
Disposition	Common Stock	6,725	$0.00	--
Disposition	Common Stock	9,656	$0.00	--

Holdings After Transaction: Common Stock — 9,656 shares (Direct)

Footnotes (1)

1. On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share ("Common Stock"), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration"). At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Popovits Kimberly J

(Last) (First) (Middle)

C/O EXACT SCIENCES CORP.

5505 ENDEAVOR LANE

(Street)

MADISON WISCONSIN 53719

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
EXACT SCIENCES CORP [ EXAS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/23/2026		D		6,725	D	(1)	9,656	D
Common Stock	03/23/2026		D		9,656	D	(2)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share ("Common Stock"), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration").

2. At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding.

	/s/ Kimberly J. Popovits by Mark Busch, attorney-in- fact	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What does this Form 4 filing show for EXACT SCIENCES CORP (EXAS)?

The filing shows director Kimberly J. Popovits disposed of all her Exact Sciences common stock as part of the merger with Abbott Laboratories. Her shares were cancelled and converted into cash at a fixed merger price per share.

At what price were EXAS shares converted in the Abbott merger?

Each share of Exact Sciences common stock was converted into the right to receive $105.00 in cash, without interest. This fixed cash amount, known as the merger consideration, applied to issued and outstanding shares at the merger’s effective time, subject to limited exceptions.

What happened to Kimberly Popovits’s EXAS restricted shares in the merger?

All Exact Sciences restricted shares held by Kimberly Popovits became fully vested at the merger’s effective time. Those shares were then cancelled and converted into the right to receive the same $105.00 cash merger consideration per share, less any applicable tax withholding obligations.

Does Kimberly Popovits still own ANY Exact Sciences (EXAS) stock after this transaction?

No. After the reported dispositions, her total Exact Sciences common stock holdings were reduced to zero shares. The filing shows all of her direct holdings were cancelled in exchange for the cash merger consideration paid in the Abbott acquisition transaction.

What corporate transaction involving EXAS does this filing relate to?

The filing relates to the merger in which Exact Sciences became a wholly owned subsidiary of Abbott Laboratories. A wholly owned Abbott subsidiary merged into Exact Sciences, and each outstanding share was converted into the right to receive the agreed cash merger consideration.

How were EXAS equity awards treated in the Abbott acquisition?

Each share of Exact Sciences common stock that was subject to vesting or other lapse restrictions was deemed fully vested at the merger’s effective time. These now-vested shares were cancelled and converted into the right to receive the $105.00 cash merger consideration, net of required tax withholding.